Documents

H-004

Supelco

Hydromorphone solution

1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Empirical Formula (Hill Notation):
C17H19NO3
CAS Number:
Molecular Weight:
285.34
EC Number:
MDL number:
PubChem Substance ID:
NACRES:
NA.24
Pricing and availability is not currently available.

Quality Level

grade

certified reference material

CofA

certificate is enclosed in each package

packaging

ampule of 1 mL

mfr. no.

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

concentration

1 mg/mL in methanol

Featured Industry

Pharmaceutical (small molecule)

format

single component solution

storage temp.

−20°C

SMILES string

CN1CC[C@@]23[C@H]4CCC(=O)[C@@H]2Oc5c(O)ccc(C[C@@H]14)c35

InChI

1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1

InChI key

WVLOADHCBXTIJK-YNHQPCIGSA-N

Gene Information

human ... OPRM1(4988)

General description

A certified reference standard suitable for use as a starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from forensic analysis, clinical toxicology, and pain prescription monitoring to urine drug testing and pharmaceutical research. Hydromorphone, marketed under brand names including Palladone and Dilaudid®, is a very potent opioid analgesic. The drug is often used medicinally as an alternative to morphine for treatment of pain or as a cough suppressant for painful coughing resulting from continued bronchial irritation.

Legal Information

CERILLIANT is a registered trademark of Cerilliant Corporation
Dilaudid is a registered trademark of Purdue Pharma L.P.

Signal Word

Danger

Target Organs

Eyes

Hazard Codes

F,T

Risk Statement

11-23/24/25-39/23/24/25

Safety Statement

7-16-36/37-45

RIDADR

UN1230 - class 3 - PG 2 - Methanol, solution

WGK Germany

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificate of Analysis
Certificate of Origin
Kyung Hee Lee et al.
Journal of opioid management, 8(4), 243-252 (2012-09-04)
To evaluate the effectiveness of OROS® hydromorphone in reducing breakthrough pain (BTP) medication frequency in Korean patients with chronic cancer pain. Multicenter, prospective, open-label, phase IV study. Patients with chronic malignant pain using immediate-release oxycodone more than two times per...
Brandon A Van Noord et al.
Journal of clinical anesthesia, 25(2), 146-149 (2013-01-22)
A 35 year old woman, 6 days after ileal neobladder construction, reported uncontrolled pain despite 33 mg hydromorphone via patient-controlled analgesia (PCA). Abdominal compartment syndrome was suspected based on worsening tachypnea, oxygen desaturation, and severe, prolonged ileus. Following emergent intubation...
Martin E Hale et al.
Journal of opioid management, 8(5), 299-314 (2012-12-19)
This analysis was designed to assess the pooled safety and tolerability of once-daily hydromorphone extended release (ER) (OROS® hydromorphone ER) in opioid-naïve and opioid-tolerant patients with chronic cancer or noncancer pain. Safety results were pooled from 13 controlled and uncontrolled...
Alec B O'Connor et al.
Journal of opioid management, 8(6), 403-413 (2012-12-25)
The reasons providers choose one parenteral opioid over another are not well understood. The authors sought to determine why emergency department (ED) providers choose one parenteral opioid over another. In a cohort of ED patients who received intravenous morphine or...
Erik Rauch
AANA journal, 80(4 Suppl), S25-S32 (2012-12-20)
Despite compelling evidence for the safety and efficacy of intrathecal hydromorphone, the use of this opioid intrathecally for the pain management of patients undergoing cesarean delivery has not been widely accepted. The purpose of this retrospective study was to compare...
Articles
Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.
Read More
Protocols
To optimize hydrolysis using β-glucuronidase, factors such as incubation time, temperature, hydrolysis pH, enzyme source, and enzyme concentration must be evaluated for each glucuronide metabolite to be analyzed.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.